FDA Peptide Ruling: Recent regulatory developments have dominated conversations around Hims & Hers Health, with an FDA advisory committee vote on compounded peptides triggering sharp market moves and renewed focus on the company's strategic positioning in wellness treatments.
Long-Term Growth Outlook: Analysts highlight the company's pivot toward branded GLP-1 offerings and peptide expansion as a potential multi-billion-dollar opportunity, emphasizing resilient subscriber growth and raised revenue guidance despite short-term volatility from competitive pressures.
Technical Momentum: Discussions underscore clean chart patterns and institutional accumulation signals, with many viewing the recent pullback as a setup for substantial upside driven by recurring revenue models and management execution.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 133,499 shares for an estimated $3,781,155.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,316 shares for an estimated $2,843,915.
- DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
- MOHAMED ELSHENAWY (CTO) sold 30,040 shares for an estimated $946,260
- PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,726 shares for an estimated $830,410
- IRENE BECKLUND (PAO) has made 0 purchases and 3 sales selling 17,592 shares for an estimated $507,029.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 3 sales selling 18,926 shares for an estimated $473,439.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Hims & Hers Health Revenue
Hims & Hers Health had revenues of $608.1M in Q1 2026. This is an increase of 3.77% from the same period in the prior year.
You can track HIMS financials on Quiver Quantitative's HIMS stock page.
You can access data on HIMS stock through the Quiver Quantitative API.
Hims & Hers Health Hedge Fund Activity
We have seen 233 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 246 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS removed 14,322,912 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $297,343,653
- GOLDMAN SACHS GROUP INC removed 7,892,648 shares (-76.3%) from their portfolio in Q1 2026, for an estimated $163,851,372
- DEFIANCE ETFS, LLC added 7,424,258 shares (+inf%) to their portfolio in Q1 2026, for an estimated $154,127,596
- MORGAN STANLEY added 4,959,856 shares (+126.2%) to their portfolio in Q1 2026, for an estimated $102,966,610
- FARALLON CAPITAL MANAGEMENT LLC removed 3,376,986 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $70,106,229
- BANK OF AMERICA CORP /DE/ added 2,877,550 shares (+194.4%) to their portfolio in Q1 2026, for an estimated $59,737,938
- RENAISSANCE TECHNOLOGIES LLC removed 2,699,929 shares (-56.0%) from their portfolio in Q1 2026, for an estimated $56,050,526
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 13 analysts offer price targets for $HIMS in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Allen Lutz from B of A Securities set a target price of $37.0 on 07/09/2026
- Maria Ripps from Canaccord Genuity set a target price of $40.0 on 07/01/2026
- Glen Santangelo from Barclays set a target price of $39.0 on 06/18/2026
- Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026
- Ryan MacDonald from Needham set a target price of $35.0 on 05/12/2026
- Cory Carpenter from JP Morgan set a target price of $33.0 on 05/12/2026
- Daniel Grosslight from Citigroup set a target price of $28.0 on 05/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
